Insulet Co. (PODD) Given Average Rating of “Buy” by Brokerages
Shares of Insulet Co. (NASDAQ:PODD) have been assigned a consensus recommendation of “Buy” from the twenty-one brokerages that are presently covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, six have issued a hold recommendation and twelve have given a buy recommendation to the company. The average 12 month price target among brokers that have covered the stock in the last year is $64.42.
A number of research firms recently issued reports on PODD. Barclays raised their price target on Insulet from $70.00 to $75.00 and gave the stock an “overweight” rating in a report on Monday, November 20th. Morgan Stanley raised their price target on Insulet from $55.00 to $63.00 and gave the stock an “equal weight” rating in a report on Friday, November 3rd. Zacks Investment Research lowered Insulet from a “hold” rating to a “sell” rating in a report on Thursday, October 5th. Robert W. Baird set a $65.00 price target on Insulet and gave the stock a “buy” rating in a report on Friday, October 13th. Finally, Wedbush reissued a “buy” rating and set a $65.00 price target (up previously from $60.00) on shares of Insulet in a report on Tuesday, October 10th.
In other Insulet news, Director James C. Mullen acquired 2,500 shares of the stock in a transaction on Monday, November 13th. The shares were bought at an average price of $67.45 per share, with a total value of $168,625.00. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. 1.90% of the stock is currently owned by insiders.
Insulet (NASDAQ PODD) traded up $2.29 on Friday, hitting $75.18. The stock had a trading volume of 662,461 shares, compared to its average volume of 670,331. The company has a debt-to-equity ratio of 4.65, a current ratio of 4.88 and a quick ratio of 4.42. Insulet has a twelve month low of $38.43 and a twelve month high of $78.65. The firm has a market capitalization of $4,242.47, a PE ratio of -150.36 and a beta of 1.58.
Insulet (NASDAQ:PODD) last posted its earnings results on Thursday, November 2nd. The medical instruments supplier reported ($0.04) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.10) by $0.06. Insulet had a negative return on equity of 43.85% and a negative net margin of 6.66%. The business had revenue of $121.80 million for the quarter, compared to analysts’ expectations of $114.02 million. During the same quarter in the previous year, the firm earned ($0.05) earnings per share. The business’s revenue was up 28.4% compared to the same quarter last year. equities research analysts forecast that Insulet will post -0.43 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This piece of content was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2018/01/19/insulet-co-podd-given-average-rating-of-buy-by-brokerages.html.
Insulet Company Profile
Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager (PDM).
Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.